XHKG
2190
Market cap746mUSD
Jun 06, Last price
18.76HKD
1D
0.54%
1Q
40.84%
IPO
-66.41%
Name
Zylox-Tonbridge Medical Technology Co Ltd
Chart & Performance
P/E
53.49
P/S
6.85
EPS
0.32
Div Yield, %
—
Shrs. gr., 5y
0.28%
Rev. gr., 5y
175.65%
Revenues
782m
+48.27%
Net income
100m
P
CFO
0k
-100.00%
Profile
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 782,476 48.27% | 527,754 57.97% | 334,090 87.78% | |||
Cost of revenue | 721,561 | 681,694 | 564,356 | |||
Unusual Expense (Income) | ||||||
NOPBT | 60,915 | (153,940) | (230,266) | |||
NOPBT Margin | 7.78% | |||||
Operating Taxes | 6,852 | |||||
Tax Rate | ||||||
NOPAT | 60,915 | (153,940) | (237,118) | |||
Net income | 100,256 -227.34% | (78,734) -34.61% | (120,407) -35.28% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (53,801) | (24,644) | ||||
BB yield | 1.32% | 0.58% | ||||
| Debt | ||||||
Debt current | 89,404 | 54,018 | 6,543 | |||
Long-term debt | 5,408 | 7,736 | 21,461 | |||
Deferred revenue | 8,674 | |||||
Other long-term liabilities | 15,885 | |||||
Net debt | (2,414,774) | (2,515,311) | (2,009,734) | |||
| Cash flow | ||||||
Cash from operating activities | 98,440 | (91,323) | ||||
CAPEX | (190,919) | (145,281) | ||||
Cash from investing activities | (206,241) | (95,045) | ||||
Cash from financing activities | (11,462) | (30,257) | ||||
FCF | (27,619) | (298,474) | (477,597) | |||
| Balance | ||||||
Cash | 1,282,890 | 1,510,869 | 1,860,671 | |||
Long term investments | 1,226,696 | 1,066,196 | 177,067 | |||
Excess cash | 2,470,462 | 2,550,677 | 2,021,034 | |||
Stockholders' equity | 1,111,172 | (149,506) | 857,913 | |||
Invested Capital | 2,096,623 | 3,261,442 | 2,241,309 | |||
ROIC | 2.27% | |||||
ROCE | 1.90% | |||||
| EV | ||||||
Common stock shares outstanding | 327,990 | 328,711 | 330,388 | |||
Price | 11.78 -5.31% | 12.44 -3.12% | 12.84 -45.59% | |||
Market cap | 3,863,722 -5.51% | 4,089,165 -3.61% | 4,242,182 -38.98% | |||
EV | 1,448,948 | 1,573,854 | 2,232,448 | |||
EBITDA | 60,915 | (118,060) | (203,998) | |||
EV/EBITDA | 23.79 | |||||
Interest | 1,251 | 722 | ||||
Interest/NOPBT | ||||||